RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Drug discovery company, SCYNEXIS, Inc. today announced that multiple abstracts related to the Company’s cyclophilin inhibitor, SCY-635, were accepted for presentation at the 45th Annual Meeting of the European Association for the Study of the Liver (EASL) in Vienna, Austria, April 14-18, 2010. SCY-635, a cyclophilin inhibitor, represents a new class of drugs for the treatment of hepatitis C virus (HCV) infection and is the first candidate from a broad platform of proprietary cyclophilin inhibitors developed by SCYNEXIS. Full abstracts can be viewed at the EASL website at www.easl.eu.
